Document:

Exhibit 10.2 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

EXECUTION VERSION

THIRD AMENDMENT TO OPTION AGREEMENT

This THIRD AMENDMENT
TO OPTION AGREEMENT (this “Third Amendment”), dated as of May 22, 2015, is by and among Monsanto Canada,
Inc., a Canadian corporation (“Monsanto Canada”), Tekmira Pharmaceuticals Corporation, a British
Columbia corporation (“Tekmira”), Protiva Biotherapeutics Inc., a British Columbia corporation
(“Protiva”), and Protiva Agricultural Development Company Inc., a British Columbia corporation
(the “Company”).

WHEREAS, Monsanto
Canada, Tekmira, Protiva and the Company (each a “Party” and collectively, the “Parties”)
are parties to that certain Option Agreement, dated as of January 12, 2014 (the “Option Agreement”) pursuant
to which Protiva granted to Monsanto Canada an option for Monsanto Canada to acquire all of the outstanding capital stock of the
Company from Protiva, and also provided that at the request of Monsanto Canada at the time of giving notice of exercise of that
option, Monsanto Canada may instead elect to be assigned the PadCo-Protiva License and Services Agreement, the Protiva License,
the Company Owned Intellectual Property and the other Company Licensed  Intellectual Property, if any, in the manner described
in the Option Agreement;

WHEREAS, in connection
with the signing of the Option Agreement, the Parties attached an exhibit titled “Exhibit A, Research Plan” (the “Original
Research Plan”) to the Option Agreement;

WHEREAS, the Parties
desire to amend, restate and replace the Original Research Plan as hereinafter set forth with a revised research plan attached
hereto as Annex A (the “Amended and Restated Research Plan”);

WHEREAS, the Parties
desire to extend the period during which Phase A of the Original Research Plan is to be completed and to adjust the time
at which certain payments are to be made under the Option Agreement, in each case, as set forth in this Third Amendment;

WHEREAS, concurrent
with the execution of this Third Amendment, the Parties are entering into an amendment of that certain Protiva-Monsanto Services
Agreement dated as of January 12, 2014.

NOW, THEREFORE,
in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and
subject to the conditions set forth herein, the Parties agree as follows:

1.                 
Amendment and Restatement of Exhibit A. The Amended and Restated Research Plan attached as Annex
A to this Third Amendment hereby amends, restates and replaces the Original Research Plan in its entirety.

    	 

    	 

    

2.                 
Amendment to Section 1.

(a)               
Section 1 of the Option Agreement is hereby amended by inserting the following text on the line immediately before the defined
term “Board”:

““Amendment
Effective Date” means May 22, 2015.”

(b)              
Section 1 of the Option Agreement is hereby amended by restating the defined term “Initiation Payment” to read
in its entirety as follows:

““Initiation
Payment” means the Option Phase A Initiation Payment, the Option Phase A-1 Initiation Payment, the Option Phase A-2
Initiation Payment, the Option Phase B Initiation Payment and the Option Phase C Initiation Payment.”

3.                 
Amendment to Section 2(e).

(a)               
Section 2(e)(ii) of the Option Agreement is hereby amended by inserting the following text after the final sentence
of such Section:

“No later
than five (5) Business Days following the Amendment Effective Date, Monsanto Canada shall pay to Protiva [***] (the “Option
Phase A-1 Initiation Payment”) by electronic wire as arranged with Protiva to continue Phase A of the Research
Program. No later than five (5) Business Days following [***] Monsanto Canada shall pay to Protiva [***] (the “Option
Phase A-2 Initiation Payment”) by electronic wire as arranged with Protiva to continue Phase A of the Research
Program. The Parties hereby agree that the Research Plan, as amended as of the Amendment Effective Date, provides (i) an option
for Monsanto Canada to extend the date by which Phase A was to have been completed (originally, [***]) by up to an additional [***]
from the Amendment Effective Date (the “Phase A Extension Election Period”), and
(ii) if Monsanto Canada so elects, an extension of an additional [***] commencing from the end of the Phase A Extension Election
Period in which to complete Phase A (the “Phase A Extension Period”).”

(b)              
Section 2(e)(iii) of the Option Agreement is hereby amended by inserting the following text after the final sentence
of such Section:

“The Parties
agree that the Research Plan, as amended as of the Amendment Effective Date, provides for an extension of the date by which Phase
A is to be completed and as a result also provides for a corresponding adjustment for the date by which Phase B is to be
completed.” 

(c)               
Section 2(e)(iv) of the Option Agreement is hereby amended by inserting the following text after the final sentence
of such Section:

“The Parties
agree that the Research Plan, as amended as of the Amendment Effective Date, provides for an extension of the date by which Phase
A is to be completed and as a result also provides for a corresponding adjustment for the date by which Phase C is to be completed.”

    	 

    	 

    

4.                 
Amendment to Section 3(b).

(a)               
Section 3(b)(v) of the Option Agreement is hereby amended by restating such Section to read in its entirety as follows:

“Monsanto
Canada shall pay to Protiva, within thirty (30) days after receipt of a Milestone Achievement Notice with respect to the Option
Plant Milestone A, [***] (the “Option Plant Milestone A Payment”) by electronic wire as
arranged with Protiva; provided, that upon the payment of the Option Phase A-1 Initiation Payment, the Option Plant Milestone A
Payment shall be reduced to [***].”

(b)              
Section 3(b)(vi) of the Option Agreement is hereby amended by restating such Section to read in its entirety as follows:

“Monsanto
Canada shall pay to Protiva, within thirty (30) days after receipt of a Milestone Achievement Notice with respect to the Option
Insect Milestone A, [***] (the “Option Insect Milestone A Payment”) by electronic wire
as arranged with Protiva; provided, that upon the payment of the Option Phase A-1 Initiation Payment, the Option Insect Milestone
A Payment shall be reduced to [***].”

5.                 
Miscellaneous

(a)               
Definitions. For all purposes of this Third Amendment, all capitalized terms not otherwise defined herein shall have
the meanings given to them in the Option Agreement.

(b)              
No Other Amendments. Except as set forth in this Third Amendment, the Option Agreement, as modified by this Third
Amendment, remains in full force and effect.

(c)               
Interpretation. When a reference is made in this Third Amendment to an Exhibit or Section, such reference shall be
to an Exhibit attached to or a Section included in the Option Agreement unless otherwise indicated. The headings contained in this
Third Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this Third Amendment.

(d)              
Counterparts. This Third Amendment may be executed in one or more counterparts, all of which shall be considered
one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties
and delivered to the other Parties. Delivery of an executed counterpart of this Third Amendment by facsimile or other electronic
image scan transmission shall be effective as delivery of an original counterpart hereof.

(e)               
Severability. If any one or more of the provisions contained in this Third Amendment or
the application of any such provision to any person or circumstance is held invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired
thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties
will in such an instance use their reasonable best efforts to replace the invalid, illegal or unenforceable provision(s) with valid,
legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Third Amendment.

    	 

    	 

    

(f)               
Amendments and Waivers. Except as otherwise set forth in this Third Amendment, this Third Amendment may not be modified,
amended or rescinded, in whole or part, except by a written instrument signed by the Parties. No delay or omission by any Party
hereto in exercising any right or power occurring upon any noncompliance or default by any other Party with respect to any of the
terms of this Third Amendment will impair any such right or power or be construed to be a waiver thereof. A waiver by any of the
Parties of any of the covenants, conditions or agreements to be performed by the other will not be construed to be a waiver of
any succeeding breach thereof or of any other covenant, condition or agreement herein contained.

(g)              
Applicable Law; Jurisdiction. This Third Amendment shall be governed and interpreted in accordance with the substantive
laws of the State of New York, excluding its conflicts of laws principles. In the event any action shall be brought to enforce
or interpret the terms of this Third Amendment, the Parties agree that such action will be brought in the State or Federal courts
located in New York, New York. Each of the Parties hereby irrevocably submits with regard to any action or proceeding for itself
and in respect to its property, generally and unconditionally, to the nonexclusive jurisdiction of the aforesaid courts. Each of
the Parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in
any action or proceeding with respect to this Third Amendment, (a) any claim that it is not personally subject to the jurisdiction
of the above-named courts for any reason other than the failure to lawfully serve process, (b) that it or its property is exempt
or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest
extent permitted by Applicable Law, that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum,
(ii) the venue of such suit, action or proceeding is improper, and (iii) this Third Amendment, or the subject matter hereof, may
not be enforced in or by such courts.

[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK]

    	 

    	 

    

IN WITNESS WHEREOF,
the Parties have caused this Third Amendment to be duly executed under seal as of the date first above written.

 

	
        PROTIVA BIOTHERAPEUTICS INC.

         

         

         

         

        By:                                                                                       

        Name:

        Title:

        Address:

         

         
	
        PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.

         

         

         

        By:                                                                            

        Name:

        Title:

        Address:

         

         

         

         

	
        TEKMIRA PHARMACEUTICALS CORPORATION

         

         

         

        By:                                                                                       

        Name:

        Title:

        Address:

         
	
        MONSANTO CANADA, INC.

         

         

         

         

        By:                                                                              

        Name:    Robert M. McCarroll, Ph.
        D.

        Title:      Authorized Signatory

        Address:

         

         

 

 

 

[Signature Page to Third Amendment
to Option Agreement]

    	 

    	 

    

 

 

ANNEX
A

 

AMENDED
AND RESTATED RESEARCH PLAN

 

(See Attached)

 

 

 

 

 

 

 

 

    	 

    	 

    

 

EXHIBIT A

Amended and Restated
Research Plan

 

[***]Exhibit 10.3

 

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.

 

	
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

	 	
1. CONTRACT ID CODE

	
PAGE OF PAGES

	 	 	 	 	 	 	 V	1	3
	
2. AMENDMENT/MODIFICATION NO

	
3. EFFECTIVE DATE

	4. REQUISITION/PURCHASE REQ. NO.	 	
5. PROJECT NO. (If applicable)

	

	 	

01-May-2015

	
 SEE
SCHEDULE

	 	 	 	 	 
	
6. ISSUED BY

	
CODE

	
W911QY

	
7. ADMINISTERED BY (If other than item 6)

	
CODE

	
W911QY

	
W6QK ACC-APG NATICK

CONTRACTING DIVISION BLDG 1KANSAS STREET

NATICK MA01760-5011

	
W6QK ACC-APG NATICK110
                                                                                                                          THOMAS JOHNSON DR SUITE#240

FREDERICK
                                         MD 21702 

 

	 	 	 
	 	 	 	 	 	 	 	 	 	 
	8.
NAME AND ADDRESS OF CONTRACTOR  (No., Street, County, State and Zip Code)

	 	
9A. AMENDMENT OF SOLICITATION NO.

	TEKMIRA PHARMACEUTICALS CORPORATION	 	9B. DATED (SEE ITEM 11)
	8900 GLENLYON PKY SUITE 100 

BURNABY V5J 5J8

	 X	

 10A. MOD. OF CONTRACT/ORDER NO.

W9113M-10-C-0057

	 	X	
10B. DATED (SEE ITEM 13)

14
Jul 2010

	 		
	
CODE    L8144

	 	
FACILITY CODE

	 	

	
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

		
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer

	 	
o is extended           o   is not extended.

	 	

Offer
must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the
following methods:

(a)
By completing Items 8 and 15, and returning.  copies of the amendment; (b) By acknowledging receipt of this amendment
on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and
amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE
HOUR AND DATE SPECIFIED MAY RESULT IN

REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram
or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the
opening hour and date specified.

	 
	
12. ACCOUNTING AND APPROPRIATION DATA (If required)

See Schedule

	 	 
	 	 	 	 	 	 	 	 	 	 
	
13.  THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. 

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	 	
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:  (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 	
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriate date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY
OF FAR 43.103.B.

	X	
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

Mutual Agreement by Both Parties

		
D. OTHER (Specify type of modification and authority)

	 	 	 	 	 	 	 	 	 	 
	
E.
IMPORTANT:         Contractor       o  is
not,       ☒  
is required to sign this document and return    ___     copies to the issuing
office.

	
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Modification Control Number:mmitchel151777

                                                                                    

The purpose of this modification is to extend the
delivery date of CLIN 0001 to 31 December 2015 at an additional cost and fee of $183,500, as shown in the attached summary of changes.

Proposal dated 08 April 2015 is hereby incorporated in its entirety by
reference.

All other terms and conditions remain the same and in full force and effect.

 

 

Except as provided herein, all terms and conditions ofthe document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	
15A. NAME AND TITLE OF SIGNER (Type or print)

	
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

	 
	 	 	 	 	
TEL:
                                         

	
EMAIL:  

	 
	
15B. CONTRACTOR/OFFEROR

	
15C. DATE SIGNED

	16B. UNITED STATES OF AMERICA	
16C. DATE SIGNED

	 	 	 	 	 	 	 	

	 	 
	 	 	 	 	BY	 	 	 
	 	
(Signature of person authorized to sign)

	 	 	
(Signature of Contracting Officer)

	 	 	 

 

	EXCEPTION TO SF 30 

APPROVED BY OIRM 11-84

	
30-105-04

	
STANDARD FORM 30 (Rev. 10-83)

Prescribed by GSA 

FAR (48 CFR) 53.243

			

 

    	 

    	 

    

W9113M-10-C-0057

(mmitchel151777)

Page 2 of 3

 

SUMMARY OF CHANGES

 

 

SECTION A - SOLICITATION/CONTRACT FORM

 

The total cost of this contract was increased by $183,500.00 from $121,363,697.24
to $121,547,197.24.

 

 

SECTION B - SUPPLIES OR SERVICES AND PRICES

 

CLIN 0001

The target cost has increased by $[***] from $[***] to $[***]. The target
profit/fee has increased by $[***] from $[***] to $[***].

The total cost of this line item has increased by $183,500.00 from $[***] to
$[***].

 

SUBCLIN 000107 is added as follows:

 

	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	000107	 	 	Job	 	$0.00
	
        Funding for CLIN 0001 FFP

        FOB: Destination

        PURCHASE REQUEST NUMBER: 0010618769-0001

	 	 	 	 	
         

        NET AMT
	
         

        $0.00

	 	
        ACRN AJ

        CIN: GFEBS001061876900002
	 	 	$183,500.00

 

 

SECTION E - INSPECTION AND ACCEPTANCE

 

	 	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	 	N/A	N/A	
        N/A

        
	Government

 

The following Acceptance/Inspection Schedule was added for SUBCLIN 000107:

 

 

SECTION F - DELIVERIES OR PERFORMANCE

 

The following Delivery Schedule item for CLIN 0001 has been changed from:

 

	 	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	UIC
	 	30-APR-2015	 	
        N/A

        FOB: Destination
	 

 

    	 

    	 

    

W9113M-10-C-0057

(mmitchel151777)

Page 3 of 3

 

To:

 

	 	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	UIC
	 	31-DEC-2015	 	
        N/A

        FOB: Destination
	 

 

 

 

SECTION G - CONTRACT ADMINISTRATION DATA

 

Accounting and Appropriation

 

Summary for the Payment Office

 

As a result of this modification, the total funded amount for this document
was increased by $183,500.00 from $53,069,126.24 to $53,252,626.24.

 

SUBCLIN 000107:

Funding on SUBCLIN 000107 is initiated as follows:

 

	 	ACRN: AJ	 
	 	CIN: GFEBS001061876900002
	 	Acctng  Data: 097201520160400000265Y0550506255	A.0011315.4.1.3.1	6100.9000021001
	 	Increase: $183,500.00	 
	 	Total: $183,500.00
	 	Cost Code: A5XAH

(End of Summary of Changes)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]